Research and Markets: European Parkinson's Disease Drug Pipeline Analysis 2014-2022

DUBLIN--()--Research and Markets ( has announced the addition of the "Europe Parkinson's Disease Drug Pipeline Analysis" report to their offering.

Parkinson's disease incidence has been on a rise in Europe in recent years and it most likely to continue rising in the near future. It has been estimated that currently, more than 1 million in Europe are affected by Parkinson's disease.

This figure is most likely to double by 2030. Among the most common neurodegenerative disease (after Alzheimer's disease), Parkinson's is the second most common and it is expected that with ageing population, its prevalence would grow significantly.

One of the major drivers of the Parkinson's drugs market in the Europe is the rising uptake of key current brands along with the launch of three new therapies which would help sustain the Parkinson's disease market through 2022. However, growing competition from generics would continue to restrain the market in the future. Consequently, owing to competitive forces, the total sales of therapies used to treat the disease would remain relatively flat over the next decade.

Europe Parkinson's Disease Drug Pipeline Analysis gives comprehensive insight on the various drugs being developed for the treatment of Parkinson's disease. Research report covers all the ongoing drugs being developed in various development phases.

This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the European Parkinson's Disease drug market based upon development process.

Following parameters for each drug profile in development phase are covered in -Europe Parkinson's Disease Drug Pipeline Analysis- research report:

  • Drug Profile Overview
  • Alternate Names for Drug
  • Active Indication
  • Phase of Development
  • Mechanism of Action
  • Brand Name
  • Patent Information
  • Country for Clinical Trial
  • Owner / Originator/ Licensee/Collaborator
  • Administrative Route
  • Drug Class
  • ATC Codes

Europe Parkinson's Disease Drug Pipeline by Clinical Phase:

  • Research: 12
  • Clinical: 26
  • Phase-I: 14
  • Phase-I/II: 2
  • Phase-II: 6
  • Phase-II/III: 1
  • Phase-III: 3
  • Preregistration: 1
  • Marketed: 18

For more information visit


Research and Markets
Laura Wood, Senior Manager.
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals


Research and Markets
Laura Wood, Senior Manager.
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals